PHAT Share Price Performance
US$9.40
-2.35 (-20.00%)
52.7% undervalued intrinsic discount
US$19.88
Fair Value
Price US$9.40
AnalystConsensusTarget US$19.88
Fair ValueUS$19.88
Share PriceUS$9.40
52.7% undervalued intrinsic discount
PHAT Community Narratives
AN
Fair Value US$19.88 52.7% undervalued intrinsic discount
Focused VOQUEZNA Marketing And Cost Cuts Will Secure 2032 Exclusivity
0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
Recent PHAT News & Updates
No updates
Phathom Pharmaceuticals, Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -4.96
- Gross Margin
- 86.23%
- Net Profit Margin
- -422.42%
- Debt/Equity Ratio
- -166.8%
Phathom Pharmaceuticals, Inc. Competitors
About PHAT
- Founded
- 2018
- Employees
- 427
- CEO
- WebsiteView website
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
U.S. Market Performance
- 7 Days: 0.2%
- 3 Months: 12.2%
- 1 Year: 19.9%
- Year to Date: 7.6%
The Communication Services sector gained 3.4% while the market remained flat over the last week. More promisingly, the market is up 22% over the past year. Looking forward, earnings are forecast to grow by 15% annually. Market details ›
This week, we are weighing up the potential productivity gains vs job losses and economic disruption that the global economy could face over the next decade and beyond.
Continue reading